Compare INTT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | KZIA |
|---|---|---|
| Founded | 1981 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.2M | 154.5M |
| IPO Year | 1997 | 2002 |
| Metric | INTT | KZIA |
|---|---|---|
| Price | $11.14 | $12.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.50 | ★ $19.50 |
| AVG Volume (30 Days) | 117.4K | ★ 252.2K |
| Earning Date | 05-05-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $15.82 | N/A |
| Revenue Next Year | $9.10 | N/A |
| P/E Ratio | $179.50 | ★ N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $7.07 | $4.86 |
| 52 Week High | $20.00 | $17.40 |
| Indicator | INTT | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 33.93 | 43.25 |
| Support Level | $7.36 | $11.39 |
| Resistance Level | $10.88 | $14.79 |
| Average True Range (ATR) | 0.59 | 1.22 |
| MACD | -0.10 | -0.20 |
| Stochastic Oscillator | 11.48 | 1.75 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.